Fidelis Capital Partners LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Fidelis Capital Partners LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 1.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,568 shares of the biopharmaceutical company’s stock after buying an additional 412 shares during the period. Fidelis Capital Partners LLC’s holdings in Pfizer were worth $709,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Wellington Management Group LLP boosted its holdings in shares of Pfizer by 4.9% in the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after acquiring an additional 11,099,024 shares during the last quarter. Swedbank AB acquired a new position in Pfizer during the first quarter valued at $172,902,000. Pzena Investment Management LLC boosted its holdings in Pfizer by 181.6% in the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after purchasing an additional 4,947,000 shares during the last quarter. Ruffer LLP grew its position in Pfizer by 248.7% during the 4th quarter. Ruffer LLP now owns 5,796,012 shares of the biopharmaceutical company’s stock worth $166,837,000 after purchasing an additional 4,133,786 shares during the period. Finally, FIL Ltd raised its stake in shares of Pfizer by 97.1% during the 4th quarter. FIL Ltd now owns 7,582,518 shares of the biopharmaceutical company’s stock valued at $218,301,000 after buying an additional 3,734,595 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $29.42 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock’s 50 day simple moving average is $29.36 and its 200-day simple moving average is $28.24. The company has a market cap of $166.71 billion, a PE ratio of -490.25, a price-to-earnings-growth ratio of 1.05 and a beta of 0.68. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.11.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.71%. Pfizer’s payout ratio is -2,799.53%.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, September 16th. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.